Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Sintilimab Versus Axitinib or Everolimus as Second-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (FRUSICA-2)

NCT05522231 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT05522231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05522231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Sintilimab Versus Axitinib or Everolimus as Second-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (FRUSICA-2)
Lead sponsor
Hutchmed
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
October 27, 2022
Completion date
March 31, 2025
Enrollment
265 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma